Retirement Systems of Alabama Raises Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Retirement Systems of Alabama raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 390,082 shares of the biopharmaceutical company’s stock after purchasing an additional 814 shares during the period. Retirement Systems of Alabama owned 0.31% of Halozyme Therapeutics worth $18,650,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in shares of Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after buying an additional 30,901 shares in the last quarter. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Boston Trust Walden Corp lifted its stake in Halozyme Therapeutics by 28.0% in the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after purchasing an additional 191,465 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Halozyme Therapeutics by 6.2% in the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after purchasing an additional 31,871 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its holdings in shares of Halozyme Therapeutics by 28.9% in the third quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company’s stock valued at $27,883,000 after purchasing an additional 109,283 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $57.94 on Friday. The firm has a 50 day moving average of $51.18 and a two-hundred day moving average of $54.38. The stock has a market capitalization of $7.37 billion, a PE ratio of 19.19, a P/E/G ratio of 0.43 and a beta of 1.25. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 52 week low of $34.36 and a 52 week high of $65.53.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on HALO shares. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $60.89.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.